ROP drug granted orphan designation

Article

Iplex (mecasermin rinfabate), a complex of recombinant human insulin-like growth factor-I (rhIGF-I) and its predominant binding protein IGFBP-3 (rhIGFBP-3) developed for the treatment of retinopathy of prematurity (ROP), has been granted orphan drug designation by the EMEA, according to a statement from Iplex developers Insmed Inc and Premacure AB.

Iplex (mecasermin rinfabate), a complex of recombinant human insulin-like growth factor-I (rhIGF-I) and its predominant binding protein IGFBP-3 (rhIGFBP-3) developed for the treatment of retinopathy of prematurity (ROP), has been granted orphan drug designation by the EMEA, according to a statement from Iplex developers Insmed Inc and Premacure AB.

The orphan designation entitles Premacure to assistance and reduced fees for pre- and post-authorization activities.

Iplex is currently approved in the US for the treatment of growth failure in children. Premacure intends to launch a multicentre Phase II trial of Iplex in the ROP indication during the second quarter of this year, and to continue investigating the drug for other indications.

Related Videos
Ramin Tadayoni, MD, speaks with Sheryl Stevenson
Jennifer I. Lim, MD, FARVO, FASRS, Director of Retina Service, University of Illinois at Chicago
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center
Carl D. Regillo, MD, FACS, FASRS, Chief of Retina Service, Wills Eye Hospital, Philadelphia, PA
Arshad Khanani, MD, MA FASRS, on a virtual call
Diana Do, MD, Professor of Ophthalmology, Byers Eye Institute, Stanford University, discusses the PHOTON study results as presented AAO
Penny A Asbell, MD, FACS speaks at the 2023 AAO meeting
© 2024 MJH Life Sciences

All rights reserved.